阿帕替尼联合替吉奥二线治疗复发性转移食管癌患者的效果

Effects of Apatinib combined with S-1 in second-line treatment of patients with recurrent metastatic esophageal cancer

目的:观察阿帕替尼联合替吉奥二线治疗复发性转移食管癌患者的效果。方法:选取72例复发转移食管癌患者作为研究对象,按照抛硬币法分为对照组和观察组各36例。对照组采用奥沙利铂联合替吉奥治疗,观察组采用阿帕替尼联合替吉奥治疗,比较两组治疗前后体液免疫指标水平、肿瘤相关生存时间与肿瘤转移情况、临床近期治疗效果及不良反应发生率。结果:治疗后,观察组免疫球蛋白G(IgG)、IgA、IgM水平均明显高于对照组,差异有统计学意义(P<0.05);随访1年,观察组总生存率、无疾病生存率、局部无复发生存率、无远处转移生存率均明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组客观有效率、疾病控制率均明显高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿帕替尼联合替吉奥二线治疗复发性转移食管癌患者,可提高体液免疫指标水平和近期治疗效果,改善肿瘤相关生存时间与肿瘤转移情况,其效果优于奥沙利铂联合替吉奥二线治疗效果。

Objective:To explore effects of Apatinib combined with S-1(Tegafur Gimeracil Oteracil Potassium capsule)in second-line treatment of patients with recurrent metastatic esophageal cancer.Methods:72 patients with recurrent metastatic esophageal cancer were selected as the research objects and divided into control group and observation group according to the coin tossing method,36 cases in each group.The control group was treated with Oxaliplatin combined with S-1,while the observation group was treated with Apatinib combined with S-1.The levels of humoral immunity indicators,tumor-related survival time and tumor metastasis,clinical short-term treatment effects and incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of immunoglobulin G(IgG),IgA,and IgM in the observation group were significantly higher than those in the control group,and the differences were statistically significant(P<0.05).At 1 year follow-up,the overall survival rate,disease-free survival rate,local recurrence-free survival rate,and distant metastasis-free survival rate of the observation group were significantly higher than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the objective effective rate and disease control rate of the observation group were significantly higher than those of the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Apatinib combined with S-1in the second-line treatment of the patients with recurrent metastatic esophageal cancer can improve the levels of humoral immune indicators and short-term treatment effects,and improve tumor-related survival time and tumor metastasis.Moreover,it is superior to Oxaliplatin combined with S-1.